Entinostat (MS-275, SNDX-275): Selective HDAC1/3 Inhibitor for Cancer Research

Executive Summary: Entinostat (MS-275, SNDX-275) is a highly selective oral inhibitor of class I histone deacetylases (HDAC1, HDAC3, HDAC8) with IC₅₀ values of 0.368 μM, 0.501 μM, and 63.4 μM, respectively (APExBIO, product page). Its mechanism involves chromatin remodeling and transcriptional reactivation of tumor suppressor genes, leading to cell cycle arrest and apoptosis (Schwartz 2022, DOI). Entinostat displays broad anti-proliferative activity across breast, colon, lung, myeloma, ovary, pancreas, prostate, and leukemia models (APExBIO; Schwartz 2022). Clinical trials report tolerable safety and define dosing regimens for combination therapy. The compound is provided as a solid (SKU: A8171), with optimal solubility in DMSO and ethanol, and should be stored at -20°C (APExBIO).

Biological Rationale

Histone deacetylases (HDACs) are epigenetic regulators that remove acetyl groups from lysine residues on histone tails, condensing chromatin and repressing gene transcription. Dysregulated HDAC activity is implicated in cancer by silencing tumor suppressor genes and facilitating oncogene expression (Schwartz 2022). Targeting HDACs, especially class I enzymes (HDAC1, HDAC3, HDAC8), can reactivate tumor suppressors, modulate cell cycle regulators, and induce apoptosis in malignant cells. Entinostat is designed for oral administration, offering pharmacokinetic advantages over earlier HDAC inhibitors. By specifically inhibiting HDAC1 and HDAC3 at sub-micromolar concentrations, Entinostat provides a focused tool for dissecting HDAC-dependent oncogenic pathways and assessing the role of epigenetic modulation in cancer therapy.

Mechanism of Action of Entinostat (MS-275, SNDX-275)

Entinostat acts as an orally bioavailable inhibitor of class I HDACs, showing strong selectivity for HDAC1 (IC₅₀ = 0.368 μM) and HDAC3 (IC₅₀ = 0.501 μM), with substantially reduced activity against HDAC8 (IC₅₀ = 63.4 μM) (APExBIO). By inhibiting these enzymes, Entinostat increases histone acetylation, leading to chromatin relaxation and reactivation of genes silenced in cancer, including p21^CIP1/WAF1 and other tumor suppressor loci. This epigenetic reprogramming triggers G1 cell cycle arrest, increased reactive oxygen species (ROS), caspase-3/7 activation, and the induction of apoptosis (Schwartz 2022). The compound is ineffective against non-class I HDACs at tested concentrations, supporting its mechanistic specificity.

Evidence & Benchmarks

• Entinostat inhibits HDAC1 and HDAC3 with IC₅₀ values of 0.368 μM and 0.501 μM, respectively, as measured in vitro using recombinant enzymes (APExBIO, product page).
• It induces G1 cell cycle arrest and apoptosis in breast, colon, lung, myeloma, ovary, pancreas, prostate, and leukemia cell lines (Schwartz 2022, DOI).
• Systemic administration in murine models of retinoblastoma increases acetyl-histone levels and reduces tumor burden (APExBIO, product page).
• Phase I clinical studies demonstrate tolerable safety and establish recommended phase II doses when combined with 13-cis retinoic acid in advanced solid tumors (Schwartz 2022, DOI).
• The anti-proliferative effect is associated with increased ROS and caspase-3/7 activation, as quantified by biochemical assays (Schwartz 2022, DOI).

For deeper mechanistic insight, see the article "Entinostat (MS-275): Next-Generation HDAC1/3 Inhibitor", which primarily addresses translational and retinoblastoma-specific contexts; the current article expands on in vitro mechanistic benchmarks and workflow integration.

Applications, Limits & Misconceptions

Entinostat is widely used in oncology research to study epigenetic modulation, tumor suppressor gene reactivation, and apoptosis induction. Its oral bioavailability and selectivity make it suitable for both in vitro and in vivo models. Key applications include:

• In vitro assessment of cancer cell proliferation and death using relative and fractional viability assays (Schwartz 2022, DOI).
• Preclinical evaluation of retinoblastoma and other solid tumors in murine and rat models (APExBIO).
• Combination therapy studies, notably with retinoic acid derivatives in clinical settings (Schwartz 2022).

Related work, such as "Entinostat (MS-275, SNDX-275): Selective Oral HDAC1/3 Inhibitor", focuses on effects across tumor types; this article clarifies specific solubility, workflow, and storage parameters.

Common Pitfalls or Misconceptions

• Entinostat is insoluble in water and should be dissolved only in DMSO or ethanol with proper warming and ultrasonic assistance (APExBIO).
• Long-term storage of prepared solutions is not recommended; stock solutions are stable at -20°C for several months but should be freshly prepared for experiments (APExBIO).
• It has limited activity against class II HDACs and is not suitable for interrogating non-class I HDAC-dependent pathways (APExBIO).
• The anti-cancer effects observed in cell lines do not always translate directly to clinical efficacy without further validation (Schwartz 2022).
• Relative viability and fractional viability measure different aspects of drug response and should not be used interchangeably (Schwartz 2022).

For additional protocol troubleshooting and advanced workflow design, see "Entinostat (MS-275): HDAC1/3 Inhibition for Advanced Cancer Research". This article provides new guidance on compound handling and storage that extends beyond standard reviews.

Workflow Integration & Parameters

Entinostat (MS-275, SNDX-275) is supplied as a solid (SKU: A8171) by APExBIO (product page). For in vitro use, dissolve in DMSO (≥18.8 mg/mL) or ethanol (≥7.4 mg/mL) with ultrasonic assistance and warming to 37°C as needed. Store stock solutions at -20°C for up to several months; avoid repeated freeze-thaw cycles and long-term storage of working solutions. For in vivo studies, administer systemically to murine or rat models following institutional protocols. Monitor acetyl-histone levels in target tissues to confirm pharmacodynamic activity. Relative and fractional viability assays, such as those described in Schwartz 2022, should be employed to differentiate growth inhibition from cell death. Results are most interpretable when linked to direct quantification of acetylation and apoptotic markers. Researchers should validate dosing and timing empirically for each experimental system.

Conclusion & Outlook

Entinostat is a benchmark small-molecule tool for selective inhibition of class I HDACs, enabling precise dissection of epigenetic mechanisms in cancer. Its proven efficacy in various preclinical models, favorable safety profile in combination trials, and defined solubility/storage parameters support its continued use in translational oncology research. Careful protocol adherence and mechanistic readouts are critical for maximizing its scientific value. As the field advances toward more personalized epigenetic therapies, Entinostat remains a foundational resource for both mechanistic studies and therapeutic development (Schwartz 2022; APExBIO).